3TC & survival

3TC & survival

AIDS Treatment Update, No. 44, August 1996
Edward King

A meta-analysis of four trials in which the combination of AZT plus 3TC was compared with a control arm of AZT alone or AZT plus ddC concluded that the combination was associated with a reduction in disease progression of between 49% and 66%.

The four trials were designed to look at the effects of the combination on surrogate markers, not clinical events, so this conclusion should be treated with some caution. Nevertheless, the results of a different trial specifically designed to look at the effects of 3TC on disease progression were released on July 23rd (see page 11), and these also demonstrated a similar reduction in disease progression to that calculated in this meta-analysis.

960810
ATU4413

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1996 - AIDS Treatment Update. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. NAM Publications 16a Clapham Common Southside, London, England SW4 7AB; TEL: 01-71-627-3200 (from outside the UK: +44-171-627-3200); FAX: 01-71-627-3101 (from outside the UK: +44=171-627-3101) info@nam.org.uk http://www.nam.org.uk

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1996. AEGIS.